Fig. 1

Patient disposition. Among 391 PD patients regularly followed up, 159 eligible patients were grouped [roxadustat group, n = 106 (66.67%); ESA group, n = 53 (33.33%)]. A total of 106 patients completed 24-week treatment [roxadustat group, n = 106 (66.67%); ESA group, n = 53 (33.33%)], whereas 20.75 and 11.32% of patients were lost to follow-up and 13.21%, and 20.75% discontinued intervention in the roxadustat and ESA groups, respectively